Heart Surgery Drug Trasylol Linked to Deaths

Trasylol is a proteinase inhibitor drug used to control bleeding during heart surgery. In 2006, studies showed Trasylol increased the risk of kidney deterioration, heart attack, stroke, and sudden death.

The Food and Drug Administration (FDA) approved Trasylol (aprotinin) in 1993 for use with slowing the loss of blood during cardiopulmonary bypass surgery, thus avoiding a need for a blood transfusion.

In 2006, both the New England Journal of Medicine and the Ischemia Research and Education Foundation reported that patients who were administered Trasylol were twice as likely to suffer a:

• Kidney failure
• Renal dysfunction
• Heart attack
• Heart failure
• Stroke
• Sudden death

Later in 2006, the FDA conducted its own study of several thousand heart attack patients and found similar results. In response to those studies, Bayer suspended all sales of Trasylol in 2007.

If you or a loved one has been injured or died after being subjected to Trasylol during heart surgery, contact the product liability attorneys at Craig Swapp & Associates for a free consultation at 1-800-404-9000 or submit your case to us on-line. An experienced Trasylol lawyer will review your situation and provide you with your legal options, so that you can be fully compensated for your injuries.